 Low-dose recombinant human erythropoietin therapy chronic hemodialysis patients hypothesis low-dose recombinant human erythropoietin r-HuEpo effective safe therapy anemia end-stage renal failure chronic hemodialysis patients months months treatment r-HuEpo IV times Hematocrit mean vol target range mean vol increase months Transfusion requirements patients new development hypertension trials doses Vascular access thrombosis dialyzer clotting seizures r-HuEpo therapy Dialyzer reuse Low-dose r-HuEpo therapy effective hemodialysis patients adverse effects increase blood viscosity targets downward dosage adjustments initial low-dose regimen